Emily Kaiser Maharjan, Assistant Managing Editor

Bonnie An Henderson, MD, program director and cofounder of EnVision Summit, shares some background on the meeting, which takes place February 14-17, 2025 in Puerto Rico.

A few optometrists share which innovations in optometry they were most excited about in 2024.

A contact lens unveiling, geographic atrophy management, and an eventful Merton C Flom Leadership Academy luncheon took center stage at last month's conference.

All 6 biomarkers in the study demonstrated improvement with the treatment of lifitegrast, according to Thimons.

In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.

Tiffany Tsoi, OD, FAAO, shares insights on the world of visual training research for eSports athletes.

Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.

Optometric insights shine brighter than the lights on the Las Vegas Strip.

Bonnie An Henderson, MD, EnVision Summit program director and cofounder, shares her perspective on the family-focused education hub.

Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.

According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.

A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting.

Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.

The dry eye drug has been assigned a PDUFA decision date of April 2, 2025, and the Aldeyra has chosen to expand their exclusive option agreement with AbbVie.

Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium

Susan Gromacki, OD, MS, FAAO, FSLS, details a panel that provided a complete course on keratoconus.

In a study, a xenon slide illuminator was employed to mimic natural outdoor colors, allowing researchers to test brightness perception using a brightness-matching method, explains Billy R. Hammond.

ODs share what they learned at this year's Academy meeting and what they plan to take home to their practices.

Tracy Doll, OD, FAAO, details portions of the Tear Film and Ocular Surface Society Lifestyle Report, which discussed certain risk factors that we may have for development of ocular surface dryness or dry eye.

Dana Shannon, OD, FAAO, details The Contact Lens Institute's latest report, "Disrupting the Dropout Dilemma."

At the 2024 American Academy of Optometry meeting in Indianapolis, Dr Andrew Pucker describes a wealth of data on enrollment in North American clinical trials.

Steve Ferrucci, OD, FAAO, discussed the detection and treatment of geographic atrophy during his AAOpt 2024 lecture, "Imaging Techniques and Emerging Therapies for Geographic Atrophy."

Jessilin Quint, OD, MBA, MS, FAAO, gives an overview on next steps after treating dry eye

Alongside Walt Whitley, OD, MBA, FAAO, Ahmad Fahmy, OD, FAAO, gave a presentation entitled, "Management of Neurotrophic Keratitis and Corneal Neuropathic Pain," at this year's AAOpt meeting.

Raman Bhakhri, OD, FAAO, breaks down the complex process of diagnosing inherited retinal diseases.

Erin Tomiyama, OD, PhD, FAAO, discusses fitting lenses, young adults with binocular vision issues, and emerging presbyopia in patients.

Dr. Carolyn Majcher discusses her 2024 AAOpt talk on imaging techniques and emerging therapy for geographic atrophy.

Brooke Messer, OD, FAAO, FSLS, overviews a talk on keratoconus management.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, tackled new and exciting ways to tackle meibomian gland dysfunction alongside fellow ocular surface specialist Rana Taji, OD, MSc, FAAO, at AAOpt 2024.

In an AAOpt poster, Dr. Mark Bullimore investigates the definition of "normal progression" in myopic eyes and the change of efficacy over time.